Now Playing
|Videos|November 11, 2022
The Changing Gram-Negative Landscape
Author(s)John Parkinson
In episode 1 of this short video series, a clinician discusses his experience in what his institution is seeing as well as how they handle their treatment protocol and stewardship where possible.
Advertisement
The fallout from COVID-19 continues to show itself in a variety of ways affecting other areas within medicine. One specific example is antimicrobial-resistant (AMR) infections.
The Centers for Disease Control and Prevention (CDC) released a report earlier this year titled, COVID-19: U.S. Impact on Antimicrobial Resistance, Special Report 2022, and in the report they concluded AMR infections worsened with resistant hospital-onset infections and deaths both increasing at least 15% during the first year of the pandemic.
The federal agency looked at AMR, and the alarming increase in resistant infections starting during hospitalization, grew among seven pathogens and increases in specific pathogens including:
- carbapenem-resistant Acinetobacter; causing a 78% increase in infections
- multidrug-resistant Pseudomonas aeruginosa causing a 32% increase in infections,
- vancomycin-resistant Enterococcus (VRE); causing a 14% increase in infections, and
- methicillin-resistant Staphylococcus aureus (MRSA); causing a 13% increase in infections.
Christian Sandrock, MD, MPH, FCCP is vice chair for Quality and Safety; division vice chief of Internal Medicine; director of Critical Care; and professor of Medicine at UC Davis Medical Center can attest to an increase in carbapenem-resistance at his institution.
“The biggest one that is concerning us is carbapenem-resistance among the gram-negatives, and that has increased,” Sandrock stated. “We are a teaching institution and we had a lot of patients who were with us for a while early on in COVID on mechanical ventilation, on ECMO [Extracorporeal membrane oxygenation]; therefore you get multiple courses of antimicrobials, as such we saw resistance increasing.”
Contagion is introducing a short series of video interviews to discuss these pathogens, and Sandrock sat down in a far-ranging interview to discuss how his institution is handling treatment, protocols on about hospital-acquired bacterial pneumonia and ventilator- associated bacterial pneumonia (HABP/VABP), and his perspective on the therapy pipeline.
In this episode, Sandrock discusses what his institution is experiencing and their microbiology resources and how it affects treatment protocols and stewardship.
Advertisement
Related to this article
Resistance-guided testing targeting a single gene mutation could let clinicians safely reintroduce ciprofloxacin for the majority of gonorrhea cases still susceptible to it, sparing ceftriaxone as resistance climbs worldwide. Lao-Tzu Allan-Blitz, MD, MPH, offers insights into his work in this area.
Outcomes from treating orthopedic infection with debridement and implanted antibiotic were similar whether followed by short or standard duration of systemic antibiotic.
In this week's top infectious disease stories, a Pennsylvania teen became the state's fourth measles death in weeks, the CDC reported a 17% summer surge in rabies exposure calls, new research revisited whether cefepime raises mortality risk, a multihospital review examined ceftriaxone's safety after state alerts, and examining Legionella pneumonia diagnostics.
A retrospective multihospital study found that severe adverse events occurred at similarly low rates with ceftriaxone and other IV cephalosporins suggesting there is no evidence to support avoiding ceftriaxone despite recent health department safety alerts.
New gyrA testing guides ciprofloxacin use for gonorrhea, cutting ceftriaxone reliance while tackling resistance, access, and FDA hurdles.
A retrospective study of 225 patients across Cook County Department of Health clinics found that the novel 1-month 1HP regimen (isoniazid plus rifapentine) for latent TB infection had a completion rate comparable to standard longer regimens and was well tolerated, suggesting it may be a viable shorter alternative.
Adding bismuth to amoxicillin-vonoprazan increased efficacy of the combination for H pylori, and exceeded that of clarithromycin-based triple therapy without contributing to clarithromycin resistance.
Editor in chief Jason Gallagher, PharmD, FCCP, FIDP, FIDSA, BCPS, discusses the proposed OMB rule restricting federal grants for international research collaboration, and how it threatens infectious disease medicine's inherently borderless surveillance networks, publication access, and knowledge-sharing systems.
Advertisement
Advertisement
Trending on Contagion Live
1
How The Food Safety Surveillance Infrastructure Works in the US
2
Evaluating Ebola Vaccine Against Current Bundibugyo Species
3
Ebola and the Ongoing Tale of US Failures
4
Implanted Antibiotic Reduced Systemic Regimen for Orthopedic Infection
5